CalciMedica, Inc. (CALC)

CalciMedica, Inc. (CALC) Healthcare & Pipeline Overview

CalciMedica, Inc. is a clinical-stage biotechnology company pioneering CRAC channel inhibition for life-threatening inflammatory diseases. Their lead candidate, Auxora, addresses unmet needs in acute pancreatitis and acute kidney injury, positioning them within the rapidly evolving biopharmaceutical landscape focused on targeted immune modulation.

What Is the Investment Thesis for CALC?

CalciMedica presents a focused investment opportunity within the biotechnology sector, predicated on the potential of its CRAC channel inhibition technology. The primary value driver is the successful clinical development and regulatory approval of Auxora for its target indications, particularly acute pancreatitis and acute kidney injury. Positive Phase 2 and Phase 3 trial results would serve as significant catalysts, potentially leading to partnerships or acquisition. However, the company faces inherent risks associated with clinical-stage drug development, including trial failures, regulatory hurdles, and competition from established therapies. The company's market capitalization of $15.61M reflects the early stage of its development and the associated risks. Successful commercialization of Auxora could drive significant revenue growth, but requires substantial further investment and execution.

Based on FMP financials and quantitative analysis

CALC Key Highlights

• Lead product candidate Auxora targets significant unmet needs in acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury.
• Proprietary technology focuses on CRAC channel inhibition, a novel approach to modulating immune response in inflammatory diseases.
• Clinical-stage company with potential for significant value creation through successful clinical trials and regulatory approvals.
• Based in La Jolla, California, a prominent biotechnology hub, providing access to resources and talent.
• Market capitalization of $15.61M reflects the early stage of development and associated risks.

Who Are CALC's Competitors?

CALC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CALC's Key Strengths?

• Novel CRAC channel inhibition technology.
• Lead product candidate targeting unmet medical needs.
• Experienced management team with expertise in drug development.
• Strong intellectual property position.

What Are CALC's Weaknesses?

• Clinical-stage company with no approved products.
• Limited financial resources.
• Reliance on the success of Auxora.
• Small number of employees.

What Could Drive CALC Stock Higher?

• Phase 2/3 clinical trial results for Auxora in acute pancreatitis.
• Regulatory submissions for Auxora in target indications.
• Expansion of clinical trials to new indications.
• Strategic partnerships for development and commercialization.

What Are the Key Risks for CALC?

• Financial-distress signal — its Altman Z-Score of -35.58 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for Auxora.
• Regulatory delays or rejection.
• Competition from established therapies.
• Dependence on successful fundraising to support operations.
• Patent challenges to proprietary technology.

What Are the Growth Opportunities for CALC?

• Expansion of Auxora's indications: CalciMedica can expand Auxora's application beyond acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury to other inflammatory diseases where CRAC channel activation plays a significant role. This could include conditions like rheumatoid arthritis or inflammatory bowel disease. The market for rheumatoid arthritis therapeutics alone is projected to reach $25 billion by 2028, presenting a substantial growth opportunity.
• Strategic partnerships: CalciMedica can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of Auxora. These partnerships could provide access to funding, expertise, and established distribution networks. Collaborations can also help to expand the company's research and development capabilities and broaden its pipeline.
• Development of oral formulations: CalciMedica can develop oral formulations of CRAC channel inhibitors to broaden their accessibility and convenience. Oral formulations could be used for chronic inflammatory conditions, offering a more patient-friendly alternative to intravenous administration. The global market for oral medications is significantly larger than that for intravenous drugs, providing a substantial growth opportunity.
• Geographic expansion: CalciMedica can expand its operations beyond the United States to target international markets. This could involve establishing partnerships with local distributors or setting up its own sales and marketing infrastructure. The global market for inflammatory disease therapeutics is growing rapidly, particularly in emerging economies.
• Advancement of pipeline programs: CalciMedica can advance its other pipeline programs targeting different aspects of the inflammatory response. This could involve developing new CRAC channel inhibitors or exploring other therapeutic targets. A diversified pipeline would reduce the company's reliance on Auxora and provide multiple avenues for growth.

What Opportunities Does CALC Have?

• Expansion of Auxora's indications.
• Strategic partnerships with larger pharmaceutical companies.
• Development of oral formulations.
• Geographic expansion.

What Threats Does CALC Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from established therapies.
• Patent expiration.

What Are CALC's Competitive Advantages?

• Proprietary CRAC channel inhibition technology.
• Lead product candidate Auxora targeting unmet medical needs.
• Strong intellectual property protection for its technology and products.
• Expertise in developing therapies for inflammatory diseases.

What Does CALC Do?

CalciMedica, Inc., founded in La Jolla, California, is a clinical-stage biotechnology company dedicated to developing innovative therapies for life-threatening inflammatory diseases. The company's core technology focuses on inhibiting calcium release-activated (CRAC) channels, a crucial component in the inflammatory response. By modulating these channels, CalciMedica aims to prevent tissue and cell injury associated with severe inflammatory conditions. Their lead product candidate, Auxora, is a proprietary intravenous formulation designed to treat acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. These conditions represent significant unmet medical needs, as current treatment options are often limited and ineffective. CalciMedica's strategic focus on CRAC channel inhibition differentiates it from other biotechnology companies, potentially offering a more targeted and effective approach to managing inflammatory diseases. The company's location in La Jolla places it within a vibrant biotechnology hub, facilitating access to talent, research collaborations, and capital.

What Products and Services Does CALC Offer?

• Develop therapies for life-threatening inflammatory diseases.
• Target calcium release-activated (CRAC) channels with proprietary technology.
• Modulate the immune response to protect against tissue cell injury.
• Focus on unmet needs in severe inflammatory conditions.
• Lead product candidate is Auxora, an intravenous CRAC channel inhibitor.
• Target indications include acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury.

How Does CALC Make Money?

• Develop and commercialize novel therapeutics for inflammatory diseases.
• Focus on CRAC channel inhibition as a primary mechanism of action.
• Out-license or partner with larger pharmaceutical companies for commercialization.
• Generate revenue through product sales, licensing fees, and milestone payments.

What Industry Does CALC Operate In?

CalciMedica operates within the competitive biotechnology industry, specifically targeting the inflammatory disease market. This market is characterized by high unmet needs and significant growth potential, driven by an aging population and increasing prevalence of chronic diseases. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing therapies for inflammatory conditions. CalciMedica's focus on CRAC channel inhibition represents a differentiated approach, but it must compete with existing treatments and emerging therapies. The biotechnology industry is subject to stringent regulatory requirements and lengthy development timelines, requiring substantial capital investment and strategic partnerships.

Who Are CALC's Key Customers?

• Hospitals and medical centers treating patients with acute pancreatitis and acute kidney injury.
• Oncologists treating patients with asparaginase-associated acute pancreatitis.
• Patients suffering from life-threatening inflammatory diseases.
• Pharmaceutical companies seeking to license or acquire novel therapeutics.

FY2026 estForward Outlook

Wall Street analysts project CalciMedica, Inc. revenue of about $2.4M for fiscal 2026, with EPS near $-0.74. The estimate reflects 4 contributing analysts.

CALC Valuation & Market Position

With a $15.61M market cap, CalciMedica, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CALC's quantitative score of 26/100 is below the peer average of 76/100.

Key Financial Metrics

A current ratio of 1.61 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -126.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

CalciMedica, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.58 places it in the distress zone, a signal of elevated financial risk.

Company Profile

CalciMedica, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in La Jolla, US. The company is led by CEO A. Rachel Leheny. CALC has traded publicly since 2023.

CALC Financials

CALC Latest News

CALC Analyst Consensus

CALC MoonshotScore

What Investors Ask About CalciMedica, Inc. (CALC) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources